10-Q: Kura Oncology Advances Cancer Pipeline, Reports Q3 Losses

Kura Oncology reports significant clinical progress for its lead cancer therapies, ziftomenib, darlifarnib, and tipifarnib, alongside increased collaboration revenue, despite widening net losses in Q3 2025.

Summary

• Kura Oncology, a clinical-stage biopharmaceutical company, reported a net loss of $74.1 million for the three months ended September 30, 2025, compared to $54.4 million for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss was $197.7 million, up from $154.8 million in the prior year period.
• Collaboration revenue for the three months ended September 30, 2025, was $20.8 million, and $50.1 million for the nine months, primarily from the Kyowa Kirin License Agreement.
• Research and development expenses increased to $67.9 million for the three months and $186.7 million for the nine months ended September 30, 2025, driven by ziftomenib and darlifarnib clinical trials.
• General and administrative expenses rose to $32.8 million for the three months and $80.8 million for the nine months ended September 30, 2025, due to personnel and pre-commercial planning costs.
• Cash, cash equivalents, and short-term investments totaled $549.7 million as of September 30, 2025.
• The company expects its current cash and investments, combined with anticipated collaboration funding, to fund operations into 2027 and support the ziftomenib AML program through topline KOMET-017 results.
• The NDA for ziftomenib in relapsed/refractory NPM1-mutated AML was accepted by the FDA with Priority Review and a PDUFA target action date of November 30, 2025.
• The KOMET-001 Phase 2 trial for ziftomenib met its primary endpoint with a complete remission (CR) plus CR with full or partial hematologic recovery (CRh) rate of 22%, exceeding the historical benchmark of 12%.
• Preliminary data from darlifarnib's FIT-001 trial showed manageable safety and encouraging antitumor activity in HRAS-mutated solid tumors.
• Tipifarnib's KURRENT-HN trial demonstrated robust antitumor activity in heavily pretreated HNSCC patients with PIK3CA alterations, with an ORR of 47% at specific doses.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive, driven by significant clinical progress for ziftomenib, including FDA Priority Review and positive Phase 2 data exceeding benchmarks, and the advancement of other pipeline candidates. The substantial collaboration revenue from Kyowa Kirin and the extension of loan repayment terms also contribute positively to liquidity management. However, this is tempered by continued and increasing net losses, significant cash burn from operations, and the inherent high risks and capital requirements of clinical-stage biopharmaceutical development.

Positives

• Collaboration revenue of $20.8 million for Q3 2025 and $50.1 million for the nine months ended September 30, 2025, a new revenue stream from the Kyowa Kirin License Agreement.
• FDA accepted the New Drug Application (NDA) for ziftomenib with Priority Review, setting a PDUFA target action date of November 30, 2025.
• The KOMET-001 Phase 2 trial for ziftomenib met its primary endpoint, achieving a CR/CRh rate of 22%, surpassing the historical benchmark of 12%.
• 61% of evaluable CR/CRh responders in KOMET-001 were negative for measurable residual disease (MRD).
• Median overall survival (OS) for ORR responders in KOMET-001 was 18.4 months, significantly higher than 3.5 months for non-responders.
• Ziftomenib's safety profile in KOMET-001 was well tolerated and consistent with previously disclosed data.
• Dosing of the first patient in a new KOMET-007 cohort (ziftomenib + 7+3 + quizartinib) on October 1, 2025, indicates pipeline expansion.
• First patient dosed under the KOMET-017 protocol (two Phase 3 trials for newly diagnosed AML) on September 29, 2025, marking advancement into registrational studies.
• Preliminary data from darlifarnib's FIT-001 trial showed a manageable safety profile and encouraging antitumor activity in HRAS-mutated solid tumors.
• Darlifarnib in combination with cabozantinib in RCC showed an objective response rate (ORR) of 33-50% in ccRCC and a disease control rate of 80-100% in ccRCC.
• Tipifarnib in combination with alpelisib in HNSCC demonstrated robust antitumor activity with an ORR of 47% in heavily pretreated patients with PIK3CA alterations.
• An additional $30.0 million development milestone payment was achieved in November 2025 under the Kyowa License Agreement.
• The loan repayment terms were extended to be interest-only through May 1, 2026 (or May 1, 2027, if the Approval Milestone is satisfied).

Negatives

• Net loss increased to $74.1 million for the three months ended September 30, 2025, from $54.4 million in the prior year period.
• Accumulated deficit grew to $1.1 billion as of September 30, 2025, from $895.4 million at December 31, 2024.
• Cash and cash equivalents decreased to $95.3 million as of September 30, 2025, from $224.5 million at December 31, 2024.
• Net cash used in operating activities increased to $181.3 million for the nine months ended September 30, 2025, from $134.8 million in the prior year period, indicating higher cash burn.
• Research and development expenses significantly increased by $26.2 million for the three months and $69.0 million for the nine months ended September 30, 2025, reflecting high development costs.
• General and administrative expenses increased by $14.7 million for the three months and $27.8 million for the nine months ended September 30, 2025.
• Two cases with fatal outcomes where Differentiation Syndrome (DS) could not be ruled out as a contributing factor were adjudicated by the FDA during the ziftomenib NDA review, despite investigators suspecting alternate etiologies.

Risks

• High dependence on the success of ziftomenib, which is still in clinical development and may not receive regulatory approval or generate anticipated revenue.
• Clinical drug development is lengthy, expensive, and has an uncertain outcome; preclinical and early clinical trial results may not predict subsequent trial outcomes.
• Product candidates may cause serious adverse events or unacceptable side effects, potentially delaying, limiting, or preventing development (e.g., Differentiation Syndrome with ziftomenib).
• Failure to develop, validate, and obtain regulatory approval for a diagnostic testing platform could harm the drug development strategy and operational results.
• Incurrence of losses since inception and expectation to incur losses for several more years, with no guarantee of achieving or maintaining profitability.
• Need to obtain substantial additional capital in the future, which may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• Dependence on the collaboration with Kyowa Kirin; if Kyowa Kirin ceases development efforts or terminates the agreement, future milestone payments or royalties may not be received.
• Reliance on third-party contractors and organizations to conduct clinical trials and provide commercial supply, with risks of unsatisfactory performance or failure to meet deadlines.
• Inability to obtain, or delays in obtaining, required regulatory approvals in planned regions, which would impair commercialization and revenue generation.
• Any approved product candidate will be subject to extensive post-approval regulatory requirements, restrictions, or withdrawal from the market, with potential penalties for non-compliance.
• Inability to obtain and maintain intellectual property protection for product candidates, or insufficient breadth of protection, could allow competitors to commercialize similar products.
• Dependence on licensors to prosecute and maintain material patents and patent applications; failure by licensors could adversely impact business.
• Patent terms may be inadequate to protect competitive position for a commercially meaningful length of time.
• Difficulty in obtaining or maintaining necessary third-party intellectual property rights for the development pipeline through acquisitions and in-licenses.
• Inability to maintain the confidentiality of trade secrets or other confidential information, which would harm business and competitive position.
• Breach of license agreements could lead to loss of important license rights.
• Uncertainty in patent law and interpretation could negatively impact patent position.
• Involvement in lawsuits to protect or enforce intellectual property, which could be expensive, time-consuming, and unsuccessful.
• Intellectual property discovered through government-funded programs may be subject to federal regulations like march-in rights, limiting exclusive rights or ability to contract with non-U.S. manufacturers.
• Inability to protect intellectual property rights throughout the world, especially due to geopolitical actions.
• Failure of approved product candidates to achieve market acceptance by physicians, patients, and third-party payors.
• Inadequate sales capabilities or inability to enter into third-party agreements to sell or market product candidates, if approved.
• Substantial competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies.
• Uncertainty regarding insurance coverage and reimbursement status of newly-approved products, potentially limiting marketability and revenue.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• High dependence on the Chief Executive Officer and ability to retain key executives and qualified personnel.
• Difficulties in managing growth due to expansion of development, regulatory, operations, medical affairs, market access, marketing, and sales capabilities.
• Unfavorable global economic conditions could adversely affect business, financial condition, or results of operations.
• Compromised information technology systems or data could lead to regulatory investigations, litigation, fines, business disruptions, and reputational harm.
• Vulnerability to interruption by natural disasters, power loss, terrorist activity, and other events beyond control.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business, financial condition, results of operations, and prospects.
• Stock price may fluctuate significantly and be volatile due to various factors, some beyond control.
• Broad discretion in the use of cash, which may not be used effectively to increase common stock value.
• FINRA sales practice requirements may limit stockholders' ability to buy and sell stock.
• Resale of shares covered by effective shelf registration statements could adversely affect market price and ability to raise additional equity capital.
• Increased costs and demands on management due to compliance with laws and regulations affecting public companies.
• Failure to maintain proper and effective internal controls could impair ability to produce accurate and timely financial statements.
• Future sales and issuances of common stock or rights to purchase common stock could result in dilution and cause stock price to fall.
• Anti-takeover provisions under charter documents and Delaware law could delay or prevent a change of control.
• Exclusive forum provisions in charter documents could limit stockholders' ability to obtain a favorable judicial forum.
• Changes in tax laws or regulations that are applied adversely could have a material adverse effect on business, cash flow, financial condition, or results of operations.
• Limitations on the ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes.

Future Outlook

Kura Oncology anticipates that its current cash, cash equivalents, and short-term investments, combined with expected collaboration funding under the Kyowa License Agreement, will be sufficient to fund operating expenses into 2027. This funding is projected to support the ziftomenib AML program through topline results from the KOMET-017 clinical trials in the frontline combination setting. The company expects research and development expenses and general and administrative expenses to increase in future periods as clinical development activities for its ziftomenib and FTI programs continue and pre-commercial activities expand. Preliminary data from the darlifarnib and adagrasib combination is anticipated in 2026, and preliminary data from the KOMET-008 cohort evaluating ziftomenib in combination with gilteritinib is also expected in 2026. Phase 1b expansion cohorts of darlifarnib and cabozantinib in advanced RCC are expected to initiate in the first half of 2026. The company will need substantial additional funding in the future to continue operations, potentially through equity offerings, debt financings, or strategic partnerships.

Management Comments

• Management believes that the unaudited condensed financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of the results for the interim periods presented.
• Management evaluates estimates and judgments on an ongoing basis, which are based on historical and anticipated results and trends and on various other assumptions believed to be reasonable under the circumstances.
• Management expects research and development expenses to increase in future periods as clinical development activities for ziftomenib and FTI programs continue.
• Management expects general and administrative expenses to increase in future periods to support planned increases in research and development and pre-commercial activities.
• Management believes that cash, cash equivalents, and short-term investments as of September 30, 2025, will be sufficient to fund current operating expenses into 2027, and combined with anticipated collaboration funding, should support the ziftomenib AML program through topline results from KOMET-017.

Industry Context

Kura Oncology operates in the highly competitive clinical-stage biopharmaceutical industry, specifically focusing on precision medicines for cancer. The company's lead candidate, ziftomenib, is a menin inhibitor, a class of drugs gaining traction with recent FDA approvals (e.g., Syndax's revumenib). Kura's strategy of targeting genetically defined cancers aligns with a broader industry trend towards personalized medicine and companion diagnostics. The company's pipeline also includes farnesyl transferase inhibitors (FTIs) like darlifarnib and tipifarnib, exploring combinations with other targeted therapies, reflecting the industry's move towards combination regimens to improve outcomes and address resistance mechanisms. The significant collaboration with Kyowa Kirin highlights the importance of strategic partnerships in sharing development costs and expanding global reach for promising assets in the capital-intensive biotech sector. The increasing scrutiny on drug pricing and the impact of legislative changes like the Inflation Reduction Act are significant industry-wide challenges that could affect future commercialization and profitability.

Comparison to Industry Standards

• Ziftomenib's KOMET-001 Phase 2 trial achieved a CR/CRh rate of 22% (cumulative 23%), exceeding the historical benchmark of 12% for relapsed or refractory NPM1-mutated AML, indicating strong efficacy relative to established expectations.
• The FDA's Breakthrough Therapy Designation for ziftomenib and tipifarnib aligns with industry recognition of significant clinical improvements over existing therapies, similar to other fast-tracked oncology drugs.
• The PDUFA target action date of November 30, 2025, for ziftomenib's NDA places it in direct competition with other recently approved menin inhibitors, such as Syndax Pharmaceuticals' revumenib (Revuforj), which received FDA approval for KMT2A-rearranged acute leukemia in November 2024 and for NPM1-mutated AML in October 2025. This indicates a competitive landscape for menin inhibitors.
• The observed objective response rate (ORR) of 33-50% in ccRCC and disease control rate of 80-100% in ccRCC for darlifarnib in combination with cabozantinib are encouraging, particularly in patients with prior cabozantinib exposure, suggesting potential for improved outcomes in a challenging patient population compared to monotherapy standards.
• The 47% ORR for tipifarnib in combination with alpelisib in heavily pretreated HNSCC patients with PIK3CA alterations demonstrates robust activity, which could be competitive in a setting with limited effective options for this specific genetic subtype.

Legal Proceedings

• Currently not a party to any legal proceedings that would have a material adverse effect on results of operations or financial position.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and stock price volatility, but also stand to benefit from successful clinical development and commercialization.
• Employees are impacted by the company's growth, with increased headcount costs and share-based compensation.
• Patients and the medical community could benefit from new precision medicines for cancer, particularly ziftomenib for AML, darlifarnib for solid tumors, and tipifarnib for HNSCC.
• Creditors (e.g., Hercules Capital, Inc.) have extended loan repayment terms, indicating ongoing financial management and potential for continued interest payments.

Next Steps

• FDA PDUFA target action date for ziftomenib NDA on November 30, 2025.
• Oral presentation of preliminary data from KOMET-007 Phase 1b expansion cohort at the American Society for Hematology Annual Meeting and Exposition on December 8, 2025.
• Initiate Phase 1b expansion cohorts of darlifarnib and cabozantinib in patients with advanced RCC in the first half of 2026.
• Present preliminary clinical data from the combination of darlifarnib and adagrasib in 2026.
• Present updated dose-escalation data from the darlifarnib and cabozantinib combination in 2026.
• Anticipate presenting preliminary data from the KOMET-008 cohort evaluating ziftomenib in combination with gilteritinib in 2026.
• Continue site activation and patient enrollment in the KOMET-017 Phase 3 trials for newly diagnosed AML.
• Expect topline results from the MRD-negative CR accelerated endpoint in the KOMET-017-IC trial in 2028.
• Evaluate data generation options for the combination of darlifarnib and a PI3Kalpha inhibitor in HNSCC and other PI3Kalpha-driven solid tumors.
• Continue to advance next-generation menin inhibitor drug candidates, including one for evaluation in diabetes.

Key Dates

Recommendation

Kura Oncology presents a mixed financial picture with increasing losses and cash burn, typical for a clinical-stage biopharmaceutical company. However, the significant clinical advancements for ziftomenib, including FDA Priority Review and positive Phase 2 data exceeding historical benchmarks, are strong catalysts. The substantial collaboration with Kyowa Kirin provides a significant revenue stream and shared development costs, bolstering the company's financial runway. The extension of loan repayment terms also offers some liquidity relief. While the PDUFA date for ziftomenib is a major near-term event that could significantly impact the stock price, the company still faces considerable risks related to regulatory approval, competition, and the need for future capital. A 'hold' recommendation is appropriate as investors await the outcome of the ziftomenib NDA and further clinical data, balancing the promising pipeline against the ongoing financial challenges and inherent industry uncertainties.

Keywords

Kura Oncology, Ziftomenib, AML, Acute Myeloid Leukemia, NPM1-mutated, Menin Inhibitor, Darlifarnib, KO-2806, Farnesyl Transferase Inhibitor, FTI, Solid Tumors, RCC, NSCLC, Tipifarnib, HNSCC, PI3Kalpha Inhibitor, Clinical Trials, Biopharmaceutical, Oncology, FDA Approval, NDA, PDUFA, Kyowa Kirin, Collaboration, Precision Medicine, Cancer Treatment, Drug Development, Biotech, Clinical Stage